TME Pharma N.V. (0N6A.F)

0.1512 -0.0018 (-1.18%) As of 03:29PM CEST. Market open.

TME Pharma N.V.

Max-Dohrn-Strasse 8-10
Berlin 10589
Germany
49 30 16637082 0
https://www.tmepharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 13

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Aram Mangasarian M.B.A., Ph.D.	CEO & Member of Management Board	527.25k	N/A	1970
Ms. Ewelina Staniuk	Senior Director of Investor Relations & Business Development	N/A	N/A	N/A
Ms. Karen Ophoff	VP of HR & Legal and General Counsel	N/A	N/A	N/A
Dr. Jarl Ulf Jungnelius M.D., Ph.D.	Chief Medical Officer	N/A	N/A	1951
Dr. Heike Balzer	Senior Vice President of Finance	N/A	N/A	N/A
Dr. Dirk Eulberg M.B.A.	Senior Vice President of Project Management & Preclinical Development	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma. The company is also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy. The company was formerly known as NOXXON Pharma N.V. and changed its name to TME Pharma N.V. in July 2022. TME Pharma N.V. was founded in 1997 and is headquartered in Berlin, Germany.

Corporate Governance

TME Pharma N.V.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.